Humabs BioMed SA - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Humabs BioMed SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Humabs BioMed SA - Product Pipeline Review - 2014', provides an overview of the Humabs BioMed SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Humabs BioMed SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Humabs BioMed SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Humabs BioMed SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Humabs BioMed SA's pipeline products

Reasons to buy

- Evaluate Humabs BioMed SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Humabs BioMed SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Humabs BioMed SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Humabs BioMed SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Humabs BioMed SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Humabs BioMed SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Humabs BioMed SA Snapshot 6
Humabs BioMed SA Overview 6
Key Information 6
Key Facts 6
Humabs BioMed SA - Research and Development Overview 7
Key Therapeutic Areas 7
Humabs BioMed SA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Humabs BioMed SA - Pipeline Products Glance 12
Humabs BioMed SA - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Humabs BioMed SA - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Humabs BioMed SA - Drug Profiles 15
MAb Against HCMV 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
FI-6 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
MAb Against Autoimmune Diseases 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MAb Against Bacterial Toxins 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MAb Against Dengue 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MAb Against HBV 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MAb Against Pan-Influenza B 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MAb Against Rabies 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MAb Against RSV And MPV 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MAb Against S. aureus 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclaonal Antibody for MERS and SARS 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for RSV 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MAb Against Ebola 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MAb Against HCV 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MAb Against HSV-1/2 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MAb Against JCV And BKV 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MAb Against Tumor 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody for Undisclosed Indication 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody to Inhibit GM-CSF for Immunology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Humabs BioMed SA - Pipeline Analysis 34
Humabs BioMed SA - Pipeline Products by Target 34
Humabs BioMed SA - Pipeline Products by Molecule Type 35
Humabs BioMed SA - Pipeline Products by Mechanism of Action 36
Humabs BioMed SA - Locations And Subsidiaries 37
Head Office 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Humabs BioMed SA, Key Information 6
Humabs BioMed SA, Key Facts 6
Humabs BioMed SA - Pipeline by Indication, 2014 9
Humabs BioMed SA - Pipeline by Stage of Development, 2014 10
Humabs BioMed SA - Monotherapy Products in Pipeline, 2014 11
Humabs BioMed SA - Phase I, 2014 12
Humabs BioMed SA - Preclinical, 2014 13
Humabs BioMed SA - Discovery, 2014 14
Humabs BioMed SA - Pipeline by Target, 2014 34
Humabs BioMed SA - Pipeline by Molecule Type, 2014 35
Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2014 36